Regulators of B-cell activity in SLE: A better target for treatment than B-cell depletion?

Lupus

Volumn 18, Issue 7, 2009, Pages 575-580

  Dolff, S ^a,b   Abdulahad, W H ^a   Bijl, M ^a   Kallenberg, C G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

B cell regulation; IL 10; SLE

Indexed keywords

ABATACEPT; AUTOANTIBODY; B CELL ACTIVATING FACTOR; BELIMUMAB; CYCLOPHOSPHAMIDE; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 10 ANTAGONIST; OCRELIZUMAB; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CLINICAL TRIAL; CROSS REACTION; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; DRUG TOLERABILITY; EFFECTOR CELL; GLOMERULONEPHRITIS; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOSTIMULATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE FUNCTION; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ANTIBODIES, ANTINUCLEAR; B-LYMPHOCYTES; CELL COMMUNICATION; HUMANS; INTERLEUKIN-10; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; T-LYMPHOCYTES;

EID: 65649128143     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309102296     Document Type: Review

References (44)

1. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novelmouse with B cells but lacking serumantibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189: 1639-1648.
2. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008; 118: 3420-3430.
3. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003; 197: 489-501.
4. Lipsky PE. Systemic lupus erythematosus: An autoimmune disease of B cell hyperactivity. Nat Immunol 2001; 2: 764-766.
5. Hahn BH. Antibodies to DNA. N Engl J Med 1998; 338: 1359-1368.
6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
7. Vlahakos D, Foster MH, Ucci AA, Barrett KJ, Datta SK, Madaio MP. Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. J Am Soc Nephrol 1992; 2: 1345-1354.
8. Jacob L, Lety MA, Louvard D, Bach JF. Binding of a monoclonal anti-DNA autoantibody to identical protein(s) present at the surface of several human cell types involved in lupus pathogenesis. J Clin Invest 1985; 75: 315-317.
9. Zhao Z, Deocharan B, Scherer PE, Ozelius LJ, Putterman C. Differential binding of cross-reactive anti-DNA antibodies to mesangial cells: The role of alpha-actinin. J Immunol 2006; 176: 7704-7714.
10. Faaber P, Rijke TP, van de Putte LB, Capel PJ, Berden JH. Crossreactivity of human and murine anti-DNA antibodies with heparan sulfate. The major glycosaminoglycan in glomerular basement membranes. J Clin Invest 1986; 77: 1824-1830.
11. Sun KH, Yu CL, Tang SJ, Sun GH. Monoclonal antidouble-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis. Immunology 2000; 99: 352-360.
12. Chan OT, Madaio MP, Shlomchik MJ. B cells are required for lupus nephritis in the polygenic, Fas-intactMRL model of systemic autoimmunity. J Immunol 1999; 163: 3592-3596.
13. Steinmetz OM, Velden J, Kneissler U, et al. Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis. Kidney Int 2008; 74: 448-457.
14. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3: 944-950.
15. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002; 16: 219-230.
16. Singh A, Carson WF, Secor Jr ER, et al. Regulatory role of B cells in a murinemodel of allergic airway disease. J Immunol 2008; 180: 7318-7326.
17. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: A role in immune regulation. J Immunol 2004; 172: 3422-3427.
18. Yin Z, Bahtiyar G, Zhang N, et al. IL-10 regulates murine lupus. J Immunol 2002; 169: 2148-2155.
19. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994; 179: 305-310.
20. Llorente L, Richaud-Patin Y, Garcia-Padilla C, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1790-1800.
21. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II doseescalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
22. Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3580-3590.
23. Finckh A, Ciurea A, Brulhart L, et al.; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007; 56: 1417-1423.
24. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56: 1263-1272.
25. Isenberg D, Gordon C, Merrill J, Urowitz M. New therapies in systemic lupus erythematosus - trials, troubles and tribulations... working towards a solution. Lupus 2008; 17: 967-970.
26. Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B-cell depletion in SLE. Ann Rheum Dis 2008; 67: 1724-1731.
27. Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: Effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006; 54: 3612-3622.
28. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007; 123: 66-73.
29. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. Arthritis Res Ther 2006; 8: R83.
30. Kinoshita K, Tesch G, Schwarting A, Maron R, Sharpe AH, Kelley VR. Costimulation by B7-1 and B7-2 is required for autoimmune disease in MRL-Faslpr mice. J Immunol 2000; 164: 6046-6056.
31. Liang B, Kashgarian MJ, Sharpe AH, Mamula MJ. Autoantibody responses and pathology regulated by B7-1 and B7-2 costimulation in MRL/lpr lupus. J Immunol 2000; 165: 3436-3443.
32. Mihara M, Tan I, Chuzhin Y, et al. CTLA4Ig inhibits T celldependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 2000; 106: 91-101.
33. Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008; 58: 953-963.
34. Bijl M, Horst G, Limburg PC, Kallenberg CG. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis 2001; 60: 523-526.
35. Abe K, Takasaki Y, Ushiyama C, et al. Expression of CD80 and CD86 on peripheral blood T lymphocytes in patients with systemic lupus erythematosus. J Clin Immunol 1999; 19: 58-66.
36. Patschan S, Dolff S, Kribben A, et al. CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. Clin Exp Immunol 2006; 145: 235-242.
37. Zhou YB, Ye RG, Li YJ, Xie CM, Wu YH. Effect of anti-CD134L mAb and CTLA4Ig on ConA-induced proliferation, Th cytokine secretion, and anti-dsDNA antibody production in spleen cells from lupus-prone BXSB mice. Autoimmunity 2008; 41: 395-404.
38. Boumpas DT, Furie R, Manzi S, et al. BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 719-727.
39. Hsu BL, Harless SM, Lindsley RC,Hilbert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional andmature B cells through distinct mediators. J Immunol 2002; 168: 5993-5996.
40. Gross JA, Johnston J, Mudri S, et al. TACI and BCMAare receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-999.
41. Zhang J, Roschke V, Baker KP, et al. Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10.
42. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453-2459.
43. Furie R, Stohl W, Ginzler EM, et al.; Belimumab Study Group. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008; 10: R109.
44. Vallerskog T, Heimburger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006; 8: R167.